Cea Soriano Lucia, Bateman Brian T, García Rodríguez Luis A, Hernández-Díaz Sonia
Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, Spain; Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA.
Pharmacoepidemiol Drug Saf. 2014 Oct;23(10):1051-8. doi: 10.1002/pds.3641. Epub 2014 May 2.
This study aimed to describe the management of antihypertensive medications in pregnancy by general practitioners in the UK and compare it with current guidelines.
We used electronic medical records from The Health Improvement Network database from 1996 to 2010 to identify completed pregnancies. The study cohort included the first pregnancy identified during the study period in women aged 13-49 years. Information on both hypertension diagnoses and prescription of specific antihypertensive medications within the 90 days before the last menstrual period (LMP) and during pregnancy was ascertained from electronic medical records.
Among 148,544 eligible pregnancies, we identified 1995 (1.3%) during which the women had pre-existing hypertension diagnosed by the LMP date. Overall, the prevalence of antihypertensive medications during the first trimester was 1.5%; beta-blockers were the most commonly prescribed antihypertensive. Among women with pre-existing hypertension, 36% were prescribed an antihypertensive medication during the 90 days before the LMP. Among those, 9.6% and 22.2% had discontinued their medication by the first and second trimesters, respectively. For contraindicated drugs such as angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, the corresponding discontinuation rates were around 25% and 70%. Women who switched therapy received preferably either methyldopa or an alpha/beta-blocker.
In this population of UK pregnant women, prescription patterns of antihypertensive medications were dominated by recommended treatments, although some patients continued on contraindicated drugs throughout pregnancy or switched to preferred agents in a delayed fashion.
本研究旨在描述英国全科医生对妊娠期降压药物的管理情况,并将其与现行指南进行比较。
我们使用了1996年至2010年健康改善网络数据库中的电子病历,以识别已完成的妊娠。研究队列包括在研究期间确定的13至49岁女性的首次妊娠。从电子病历中确定末次月经(LMP)前90天内及妊娠期高血压诊断和特定降压药物处方的信息。
在148544例符合条件的妊娠中,我们识别出1995例(1.3%)在LMP日期前已诊断出患有高血压。总体而言,孕早期降压药物的使用率为1.5%;β受体阻滞剂是最常用的降压药。在患有原发性高血压的女性中,36%在LMP前90天内开具了降压药物。其中,分别有9.6%和22.2%在孕早期和孕中期停用了药物。对于禁忌药物,如血管紧张素转换酶抑制剂和血管紧张素II受体阻滞剂,相应的停药率分别约为25%和70%。更换治疗方案的女性首选甲基多巴或α/β受体阻滞剂。
在这群英国孕妇中,降压药物的处方模式以推荐治疗为主,尽管一些患者在整个孕期继续使用禁忌药物,或延迟更换为首选药物。